Olaparib and Rucaparib were recently approved for the treatment of advanced prostate cancer in men with a BRCA mutation. Moreover, knowledge of a BRCA mutation (by means of genetic testing) can also inform individuals about their risk of developing prostate cancer, breast cancer, ovarian cancer, pancreas cancer, and melanoma. Here, PCRI's Alex asks Mark Scholz, MD, all about genetic testing and the BRCA mutation.
0:06 What is BRCA testing and why is it important?
2:03 Are Rucaparib and Olaparib only available to those who have the BRCA mutation?
2:30 Is there a minimum age for BRCA testing?
3:33 At what age should someone who is BRCA-positive begin PSA testing?
5:16 Summary
Don’t know your stage? Take the quiz: Visit [ Ссылка ]
To learn more about prostate cancer visit [ Ссылка ]
Who we are:
The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians, for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better individualized care. Feel free to explore our website or call our free helpline at 1 (800) 641-7274 with any questions that you have. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.
The information on the Prostate Cancer Research Institute's YouTube channel is provided with the understanding that the Institute is not engaged in rendering medical advice or recommendation. The information provided in these videos should not replace consultations with qualified health care professionals to meet your individual medical needs.
#ProstateCancer #Prostate #MarkScholzMD
